Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

26 Jul 2010

Study focuses on health issues of PGDP workers

A five-year study into the causes of deaths of workers at Paducah Gaseous Diffusion Plant shows significantly lower death rates from all causes and cancer in general when compared to the overall United States population. This is known by occupational health researchers as the "healthy worker effect". However, death from lymphatic and bone marrow cancers such as leukemia or multiple myeloma were slightly above national rates.

23 Jul 2010

NVCI, CSN and Workforce CONNECTIONS partner to launch ARRA funded nursing internship program

Nevada Cancer Institute (NVCI) is launching its Plus One Program, a paid nursing internship initiative to equip nursing graduates with advanced training to give them an edge in today's competitive nursing job market. After completing a paid one-year internship at NVCI, participants will become oncology nurses, a highly sought-after specialty. These specialized jobs have the potential to pay increased wages, provide excellent benefits and support articulated career ladders within the field of oncology.

23 Jul 2010

ASH to honor six scientists for treatment of hematologic diseases

The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding and treatment of hematologic diseases. These awards will be presented at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando.

23 Jul 2010

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx's oncology drug candidate tamibarotene.

23 Jul 2010

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.

22 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

First Edition: July 21, 2010

Today's headlines include news regarding specific examples of what could happen at the state level if Congress doesn't extend enhanced federal Medicaid funding.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.

21 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

ThermoGenesis anticipates $7.3 million revenue for fourth-quarter 2010

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today it expects revenues for the quarter ended June 30, 2010, to be approximately $7.3 million and to report a small net loss for the quarter, in the range of $150,000 to $450,000, subject to final audit adjustments. The Company plans to report complete final results for the fourth quarter and all of fiscal 2010 and provide its outlook for fiscal 2011 in mid-September.

19 Jul 2010

New mechanism that drives development of B-lymphocytes in bone marrow discovered

Scientists from the Department of Molecular Immunology, Institute of Biology III, Faculty of Biology and the Centre for Biological Signalling Studies, BIOSS have discovered a new mechanism that drives the development of B-lymphocytes in our bone marrow. B-lymphocytes are an important part of our immune system. Upon their activation they produce the antibodies protecting us from infections.

17 Jul 2010

Biomet acquires all assets of Cytosol Laboratories

Biomet, Inc., a global leader in the manufacture of musculoskeletal medical products, announced today its acquisition of substantially all of the assets of Cytosol Laboratories, Inc., located in Braintree, Massachusetts, a market leader in production of small volume anticoagulants.

17 Jul 2010

VCU Medical Center ranked in 2010-2011 Best Hospitals

The Virginia Commonwealth University Medical Center on Thursday was ranked in the 2010-2011 Best Hospitals in the country by U.S. News and World Report, making it one of 152 medical centers nationwide selected out of nearly 2,000 eligible institutions.

16 Jul 2010

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).

14 Jul 2010

Gene therapy represents safe alternative to current cures for blood disorder β-thalassemia

Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.

14 Jul 2010

LSUHSC Professor awarded $2.1M grant to determine role of PCP

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia, which can be a complication of HIV/AIDS.

14 Jul 2010

ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML

ChemGenex Pharmaceuticals Limited announced today it has agreed with the U.S. Food and Drug Administration (FDA) on a potential regulatory path to progress OMAPRO™ (omacetaxine mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML).

14 Jul 2010

Bone Marrow News and Research

Further Reading

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Study focuses on health issues of PGDP workers

NVCI, CSN and Workforce CONNECTIONS partner to launch ARRA funded nursing internship program

ASH to honor six scientists for treatment of hematologic diseases

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Health Canada grants Osiris Priority Review for Prochymal NDS

First Edition: July 21, 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

CytRx updates on progress in clinical development of bafetinib in three oncology indications

ThermoGenesis anticipates $7.3 million revenue for fourth-quarter 2010

New mechanism that drives development of B-lymphocytes in bone marrow discovered

Biomet acquires all assets of Cytosol Laboratories

VCU Medical Center ranked in 2010-2011 Best Hospitals

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

Gene therapy represents safe alternative to current cures for blood disorder β-thalassemia

LSUHSC Professor awarded $2.1M grant to determine role of PCP

ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News